A Phase 2, Multicenter, Randomized, Double-Blind, Comparator-Controlled Study of the Efficacy, Safety, and Pharmacokinetics of Intravenous Ulimorelin (LP101) in Patients With Enteral Feeding Intolerance (EFI)

Trial Profile

A Phase 2, Multicenter, Randomized, Double-Blind, Comparator-Controlled Study of the Efficacy, Safety, and Pharmacokinetics of Intravenous Ulimorelin (LP101) in Patients With Enteral Feeding Intolerance (EFI)

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Mar 2018

At a glance

  • Drugs Ulimorelin (Primary) ; Metoclopramide
  • Indications Enteral nutrition dysfunction
  • Focus Therapeutic Use
  • Acronyms PROMOTE
  • Sponsors Lyric Pharmaceuticals
  • Most Recent Events

    • 06 Mar 2018 Status changed from recruiting to completed.
    • 05 Mar 2018 According to a Lyric Pharmaceuticals media release, Daren Heyland, M.D., M.Sc., FRCPC, professor and director, Clinical Evaluation Research Unit, Kingston Health Sciences Centre, Kingston is the Principle Investigator of the study.
    • 23 Jan 2018 Data (n=84) published in a Lyric Pharmaceuticals Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top